雷替曲塞联合奥沙利铂治疗中晚期原发性肝癌的临床研究

目的:探讨雷替曲塞联合奥沙利铂(RALOX)应用于中晚期原发性肝癌(PLC)的疗效及药物毒性反应。方法:选取34例中晚期PLC患者为观察组,对其进行RALOX方案化疗,将同期符合化疗条件但行对症支持治疗的36例中晚期PLC非化疗患者纳入对照组。每2个周期评价客观缓解率(OR)、疾病控制率(DCR)、中位生存时间(m OS)、中位无进展生存期(m PFS)、1年存活率(SR)及毒副反应。结果:观察组的OR、DCR、m OS及m PFS均明显优于对照组(P<0.05);化疗毒副反应多为轻中度消化道反应、肾毒性、肝毒性、骨髓抑制、周围神经毒性,经积极处理以上毒副反应均可缓解。结论:RALOX方案对中晚期PLC安全有效,具有良好的病情控制和生存获益,毒副反应可耐受,值得临床推广应用。

Clinical study of raltitrexed combined with oxaliplatin in the treatment of middle and advanced primary liver cancer

Objective:To explore the clinical efficacy and drug-toxic reactions of raltitrexed combined with oxaliplatin (RALOX) in the treatment of middle and advanced primary liver cancer (PLC).Methods:A total of 34 patients with middle and advanced PLC were selected as the observation group and treated with RALOX protocol,and another 36 patients with middle and advanced PLC in corresponding period and treated with symptomatic support treatment were took as the control group.Objective remission rate (OR),disease-control rate (DCR),median survival rate (mOS),median progression-free survival (mPFS),1-year survival rate (SR) as well as toxic and adverse reactions were evaluated every 2 cycle.Results:The observation group was notably better than the control group in OR,DCR,mOS and mPFS (P ＜ 0.05).The chemotherapy-induced toxic and adverse reactions were mainly mild and moderate gastrointestinal reactions,renal toxicity,liver toxicity,myelosuppression and peripheral nervous toxicity,which were relieved after positive treatment.Conclusions:RALOX protocol is safe and effective in the treatment of middle and advanced PLC,has excellent disease control and survival benefits,and is tolerable in toxic and adverse reactions,thus deserving to be widely applied in clinic.